Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women
Rosa F. Yeh(Seattle Cancer Care Alliance), Kristine B. Patterson(University of North Carolina at Chapel Hill), Ya-Chi Chen, Angela D. M. Kashuba(University of North Carolina at Chapel Hill), Hiba L. Tappouni(GlaxoSmithKline (Netherlands)), Amanda Horton, Naser L. Rezk(University of North Carolina at Chapel Hill), Hsiao‐Chuan Tien, Julie B. Dumond(University of North Carolina at Chapel Hill), Susan A. Fiscus(University of North Carolina at Chapel Hill), Manoli Vourvahis(Pfizer (United States))
Cited by 58
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
|New England Journal of Medicine|2016|348